The Effect of Post Ablation Medroxyprogesterone Acetate on Endometrial Amenorrhea Rates

NCT ID: NCT02449161

Last Updated: 2022-05-23

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE3
• Total Enrollment: 60 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2015-08-31
• Study Completion Date: 2021-05-31

Brief Summary

Heavy menstrual bleeding are a common reason for consultation in gynecology and are defined by International Federation of Gynecology and Obstetrics as the perception of menstrual volume increased regardless of the frequency, duration and regularity. Some studies report that up to 30% of women will suffer from heavy periods during their lifetime. The first line treatment of heavy bleeding is medical. However, a significant proportion of women require surgery. Until the 80s, hysterectomy was one of the only surgical options and often performed as the first line treatment. Since twenty years now the endometrial ablation has become a preferred option for dysfunctional uterine bleeding and avoids hysterectomy in a significant proportion of patients suffering from this type of problem. Endometrial ablation is much less invasive and morbid than hysterectomy, however, many patients do not achieve a complete amenorrhea with endometrial ablation and about 15% may have to require a new intervention, such as hysterectomy, following the persistence of menstrual problems. A Cochrane review published in 2013 showed that the satisfaction rate following endometrial ablation is high at 70-80% and about 35% of women have amenorrhea. The complete destruction of the endometrium is the most important predictor of the success of the procedure. Studies have shown that better results are obtained when the surgery is performed when the endometrium is thin or immediately following menses or following administration of a hormonal agent causes atrophy of the endometrium. One of the agents studied to prepare the endometrium before ablation is medroxyprogesterone acetate (MPA) as injectables (DMPA) and oral. Progestins have an antiproliferative effect on the endometrium. In recent years, numerous studies have examined the use of various agents preoperatively, including MPA and DMPA to facilitate surgery by reducing the thickness of the endometrium. However, few studies have focused on the conditions of the post-operative period to promote the therapeutic response to the intervention. The investigators hypothesis is whether the MPA administered in immediate post-operative would inhibit proliferation of endometrial cells responsible for the persistence of menstruation and optimize the clinical response to endometrial ablation.

Conditions

Menorrhagia

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

MPA

medroxyprogesterone acetate, 10 mg/day, for 90 days, following endometrial ablation

Group Type: EXPERIMENTAL

MPA

Intervention Type: DRUG

placebo

1 placebo/day, for 90 days, following endometrial ablation

Group Type: PLACEBO_COMPARATOR

placebo

Intervention Type: DRUG

Interventions

MPA

Intervention Type: DRUG

placebo

Intervention Type: DRUG

Other Intervention Names

provera

Eligibility Criteria

Inclusion Criteria

• endometrial ablation planned for eavy menstrual bleeding
• No abnormalities at hysteroscopy
• No evidence of hyperplasia or neoplasia in endometrial biopsy
• Hysterometry of ≤ 10 cm preoperatively

Exclusion Criteria

• Any indication against MPA
• Intrauterine pathology causing heavy bleeding
• hormonal treatment provided during the postoperative period (during the first 4 months)
• preoperative hormonal therapy with a residual postoperative effect
• breastfeeding
• future pregnancy planned
• menopausal women
• endometrial ablation antecedent
• Suspected pelvic infection
• known Hematologic Disease
• Taking anticoagulant
• Taking progestin in the 6 months before surgery

• Minimum Eligible Age: 25 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: No

Sponsors

CSSS Chicoutimi

UNKNOWN

Sponsor Role: collaborator

Guy Waddell

OTHER

Sponsor Role: lead

Responsible Party

Guy Waddell

MD

Responsibility Role: SPONSOR_INVESTIGATOR

Locations

Centre Hospitalier Universitaire de Sherbrooke

Sherbrooke, Quebec, Canada

Countries

Canada

Other Identifiers

MP-31-2015-998

Identifier Type: -

Identifier Source: org_study_id